This is a summary of the European public assessment report (EPAR) for Inflacam. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Inflacam.
For practical information about using Inflacam, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Inflacam : EPAR - Summary for the public (PDF/81.43 KB)
First published: 16/12/2011
Last updated: 21/12/2015
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic medicines.
Chanelle Pharmaceuticals Manufacturing Ltd
|Date of issue of marketing authorisation valid throughout the European Union||
28/10/2016 Inflacam - EMEA/V/C/002497 - IB-0013
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Anti inflammatory and antirheumatic products
Dogs: alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.
To reduce post-operative pain and inflammation following orthopaedic and soft tissue surgery.
Cats: to reduce post-operative pain after ovariohysterectomy and minor soft tissue surgery.
Cattle: for use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.
For use in diarrhoea in combination with oral re‑hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
For the relief of post-operative pain following dehorning in calves.
Pigs: for use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.
For the relief of post operative pain associated with minor soft tissue such as castration.
Horses: alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
For the relief of pain associated with equine colic.